Cancer screening can be a stressful time for pet owners. The mere prospect of a cancer diagnosis can be deeply unsettling, with owners often facing an anxious and agonizing wait for results. If a diagnosis is confirmed, navigating treatment options can be overwhelming. For veterinary professionals, the ability to offer accurate, efficient and timely diagnostics is critical in guiding clients through this process. Digital cytology is an essential part of the diagnostics process, transferring microscopic slides into high-resolution images to be viewed on a screen. This allows for cells to be examined and analysed for abnormal features to detect diseases such as cancer. Technological advances in this area are changing the game for digital cytology. Deep learning artificial intelligence (AI) integration is delivering enhanced speed and precision – supporting veterinary professionals to make more informed decisions, for better patient care. AI Masses, Zoetis’s new addition to the Vetscan Imagyst® platform, applies deep learning algorithms to assess potentially cancerous cells in common lymph node and subcutaneous lesions found during physical exams or imaging. The in-clinic screening application delivers accurate results within minutes alongside clear, detailed image-based reports, to unlock deep insights. For the veterinarian, this means being able to provide clients with answers, quickly – informing and enabling timely, individualized diagnosis and treatment decisions. As a result, diagnoses and clinic workflows can be streamlined, empowering confident case management. For the pet owner, it helps to reduce anxious wait times to allow for fast care decisions that guide the best possible outcome. Real-time insights at the point of care increase accessibility to care, helping to alleviate stress and aiding client satisfaction. In this video, Richard Goldstein DVM, Chief Medical Officer of Global Diagnostics at Zoetis, sets out why AI Masses represents “a whole new frontier” for in-clinic cancer screening. Dr John Hutchens, veterinarian and owner of Hands of Hope Animal Hospital, offers his thoughts on what the technology will mean for veterinary teams and their patients. As with Zoetis’s other AI applications, Vetscan Imagyst AI Masses requires only a single round of sample preparation, with access to expert clinical pathologist review via Digital Cytology or Add-on Expert Review*, for added diagnostic confidence. AI Masses is the latest capability to be added to Zoetis’s Vetscan Imagyst platform, making it the only commercially available veterinary diagnostics tool of its kind to offer seven unique testing applications in one compact tabletop design: AI Masses, Digital Cytology, AI Urine Sediment, AI Fecal, AI Equine Fecal, AI Dermatology, and AI Blood Smear. For more information, go to https://www.zoetisdiagnostics.com/us/point-of-care/vetscan-imagyst/ *Additional costs may apply. All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2025 Zoetis Services LLC. All rights reserved. VTS-01740
